Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases
Article first published online: 11 MAY 2012
© The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin
JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Volume 10, Issue 10, pages 727–731, October 2012
How to Cite
Kasperkiewicz, M., Eming, R., Behzad, M., Hunzelmann, N., Meurer, M., Schulze-Koops, H., von Wussow, P., Hertl, M., Zillikens, D., Freivogel, K., Dörner, T. and Schmidt, E. (2012), Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 10: 727–731. doi: 10.1111/j.1610-0387.2012.07931.x
- Issue published online: 26 SEP 2012
- Article first published online: 11 MAY 2012
- Submitted: 4.1.2012 | Accepted: 20.2.2012
- bullous disease;
- pemphigus vulgaris;
Background: Rituximab has been reported to be effective in various small case series of patients with severe and/or refractory pemphigus. However, no systematic evaluation is available to corroborate this observation. The aim of this study was to systematically determine efficacy and safety of rituximab in treatment-resistant pemphigus.
Patients and Methods: Multicenter retrospective, observational study of 36 patients with severe pemphigus vulgaris (n = 33) and pemphigus foliaceus (n = 3) treated with rituximab before August 31st, 2008 and enrolled in a national observational registery between December 2008 and June 2009.
Results: Within a mean period of observation of 11 (1–37) months, 21 (58 %) pemphigus patients showed complete, 13 (36 %) partial, and 2 (6 %) no response to rituximab treatment. This correlates with a mean improvement of the visual analog scale for well-being of 34 (20–60) at baseline to 75 (40–95) at the last control visit. In 4 (11 %) patients, severe adverse events were recorded including 1 (3 %) serious infection.
Conclusions: Data collected in this systematic registry indicate that rituximab is an effective and relatively safe adjuvant treatment option for refractory pemphigus. To further extend our knowledge on efficacy and safety of this drug, controlled prospective trials are required.